• A long-acting somatostatin analogue (lanreotide) is effective in the management of patients with congenital hyperinsulinaemic hypoglycaemia (CHI) who are unresponsive to diazoxide. • To date there are no publications regarding the effect of lanreotide in CHI patients with focal pancreatic lesions.
ide-unresponsive CHI due to a paternal heterozygous KCNJ11 gene mutation was partially responsive to octreotide. 18 F-DOPA-PET/CT scan confirmed a focal pancreatic head lesion. Over 6 months, he underwent 3 lesionectomies and afterwards responded to octreotide. At the age of 9 months, treatment was switched to monthly lanreotide. Currently, he is aged 3, with stable glycaemia, and improved fasting tolerance. Case 3: A 3-week-old girl with a paternal heterozygous ABCC8 gene mutation was unresponsive to diazoxide. 18 F-DOPA-PET/CT scan confirmed a focal pancreatic head lesion. She responded to octreotide, and her parents preferred to avoid pancreatic surgery. At the age of 20 months, treatment was switched to monthly lanreotide, resulting in euglycaemia over the last 7 months. Conclusion: CHI patients with focal pancreatic head lesions are challenging, especially if not surgically amenable. Conservative treatment is preferable, and lanreotide might be an option. The therapeutic impact of lanreotide treatment in patients with the focal forms of CHI should be confirmed in prospective studies with close monitoring of the side effects.
© 2018 S. Karger AG, Basel

Background
Congenital hyperinsulinism (CHI) is characterised by the inappropriate, excessive secretion of insulin from the pancreatic β-cells, and it is the most common cause of persistent hypoglycaemia in infancy [1] . CHI is a heterogeneous disorder with respect to clinical presentation, imaging, histology, and genetics. Mutations in at least 11 different genes (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, HNF4A, HNF1A, PMM2, and HK) have been reported so far as the genetic causes of CHI [1] [2] [3] [4] [5] . There are 2 main histological types of CHI: diffuse and focal; these are clinically identical but differ in the underlying genetic mechanism, histopathology, and management. The focal lesions are characterised by nodular hyperplasia of islet-like cell clusters with ductulo-insular complexes and scattered giant β-cell nuclei with normal surrounding tissue [6] ; whereas in the diffuse form, the entire pancreas has enlarged islets with hypertrophied β-cells.
Focal CHI results from a paternally inherited heterozygous ABCC8 or KCNJ11 gene mutation, together with a somatic loss of the maternal chromosome in the 11p15 region (most likely caused by paternal isodisomy) [6] [7] [8] . Fluorine-18 L-3, 4 dihydroxyphenylalanine positron emission tomography computed tomography ( 18 F-DOPA-PET/CT) scan can help to differentiate focal from diffuse forms of CHI and subsequently aid in the management of these patients [9] . Focal CHI is usually medically unresponsive, although diazoxide-responsive focal CHI has recently been described [10] . Targeted surgical removal of the lesion will cure the patient [11] . Sometimes, the management of focal CHI presents paediatric endocrinologists with a choice of unsatisfactory treatments either due to an inoperable position of the lesion or due to post-pancreatectomy complications such as failure to cure hypoglycaemia and eventual diabetes mellitus at puberty [11, 12] .
The 3 cases presented in this report (Table 1) pioneered a more conservative approach in successfully treating CHI patients with a focal lesion in the pancreatic head with lanreotide together with frequent feeds. Using this approach, we were able to achieve euglycaemia and normal growth. The most important aspect was the quality of life improvement, since the daily care of our patients was simpler with one injection every 4 weeks leading to improved blood glucose regulation.
Case Reports
Case 1 A 1-month-old boy, born at 38 weeks' gestation, with a birth weight of +0.05 SDS and a normal antenatal history, was diagnosed with CHI on the first day of life. He was unresponsive to maximum doses of diazoxide (20 mg/kg/day) and chlorothiazide (7 mg/kg/ day), and he was subsequently commenced on octreotide (10 μg/ kg/day given as 4 subcutaneous (sc) injections). He was fed via a nasogastric tube on a 3-hourly regimen of high-calorie milk feeds (CHO 10%), with complete aversion to oral feeds and a weight on the 99.6th centile. He continued to have episodes of hypoglycaemia and was transferred to our unit for further management. Upon arrival, his blood glucose was stabilised on intravenous (iv) fluids (20% dextrose = 4.3 mg/kg/min), octreotide injections, and 3-hourly feeds.
Genetic testing revealed a heterozygous nonsense ABCC8 gene mutation (c.2464C>T; p.Gln822Ter). 18 F-DOPA-PET/CT scan confirmed a focal lesion in the head of the pancreas (Fig. 1) . Lesionectomy via laparotomy was unsuccessfully attempted as the focal lesion was found to be extensive, occupying the pancreatic head with infiltration of the duodenum and common bile duct, requiring Whipple's procedure. Multiple pancreatic biopsies from the head and surrounding structures confirmed focal CHI. The parents were not keen to undertake radical pancreatic surgery and wished to attempt medical treatment, failing which a more extensive procedure could be planned at a later date.
Consequently, therapy with sirolimus (an mTOR inhibitor) was started (maximum: 6 mg/m 2 /day) along with 6-hourly sc octreotide injections (maximum: 40 μg/kg/day) and 2-hourly oral feeds (12% CHO) during the day and 12 h of overnight continuous 12% Vitajoule ® via percutaneous gastrostomy. Following several infections including line sepsis, and inadequate response to sirolimus, it was decided to suspend this medication.
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A trial of lanreotide (somatuline autogel) was then commenced after parental consent. Four-weekly sc lanreotide at a dose of 30 mg achieved euglycaemia, and octreotide injections were weaned over 3 months and then stopped. Over the last 12 months, the patient has been on sc lanreotide injections combined with 3-hourly oral feeds and continuous overnight 12% Vitajoule feeds via percutaneous gastrostomy. His blood glucose is stable, and he is able to fast for up to 3 h during the daytime. Consequently, his quality of life has markedly improved, and he was discharged home on 1 injection every 4 weeks, with appropriate neurodevelopmental milestones. Case 2 A 1-month-old boy was admitted for further management of CHI as he was unresponsive to diazoxide. He was born by spontaneous vaginal delivery at 38 weeks' gestation with a birth weight of +4.1 SDS and no history of maternal diabetes mellitus. A few hours after birth, he was found to be hypoglycaemic and further biochemical investigations confirmed CHI. Hence, he was commenced on diazoxide and chlorothiazide, but he was unresponsive to maximum doses. He was subsequently commenced on 6-hourly sc octreotide injections and showed a partial response to a maximal dose (40 μg/kg/day). He continued to be on 3-hourly feeds and iv dextrose (up to 12 mg/kg/min).
Sanger sequencing identified a paternally inherited heterozygous missense KCNJ11 gene mutation (p.G40D, c.119G>A). 18 F-DOPA-PET/CT scan confirmed an increased uptake of 18 F-DOPA in the head of the pancreas (SUV max 4.0) compatible with a focal lesion (Fig. 1) .
He underwent removal of the focal lesion from the head of the pancreas at the age of 3 months. The histopathology report confirmed focal endocrine cell hyperplasia. Unfortunately, after surgery, he continued to have multiple episodes of hypoglycaemia that required iv administration of high glucose concentrations, and he had to be recommenced on infusions of sc octreotide (40 μg/kg/day) and iv glucagon (5 μg/kg/h) in order to maintain normoglycaemia.
In view of persistent severe CHI, a second 18 F-DOPA-PET/CT scan was performed which showed an increase in tracer uptake in the pancreatic head/uncinate process (SUV max 7.9) with lower grade activity in the pancreatic body (SUV max 3.6). A second pancreatic resection was attempted at the age of 4 months, with removal of the whole head of the pancreas, and histopathology sections confirmed focal endocrine hyperplasia.
However, hypoglycaemia persisted, and he required continuous infusions of sc octreotide (40 μg/kg/day) and iv glucagon (5 μg/kg/h). Since the patient was not fully responsive, a trial of sirolimus (maximum 16 mg/m 2 /day) was given, but was later stopped in view of a poor response and episodes of central line sepsis, a probable side effect of sirolimus-related immunosuppression.
At 7 months of age, he continued to have hypoglycaemia, and a third pancreatic resection was attempted for removal of the residual pancreatic head and margins of distal pancreas, with formation of a Roux-en-Y anastomosis to the body of the pancreas and common bile duct. The histopathology report showed that the lesional cells expressed proinsulin and insulin, glucagon, and somatostatin with only minimal expression of pancreatic polypeptide. Ki67 immunostaining confirmed an increased proliferation in the lesional cells and normal pancreas at the resected margin. Paraffin section adjacent to this margin showed some lesional tissue in close proximity, but not at the margin.
Interestingly, after the third pancreatic resection, the patient responded to sc octreotide injections (30 μg/kg/day divided into 4 injections a day) and 3-hourly oral feeds during the day with 12 h overnight continuous gastrostomy feeds. At 9 months of age, his treatment was switched from octreotide to lanreotide 30 mg every 4 weeks. The octreotide dose was weaned gradually over 2 months and then stopped. Over the last 2.5 years, he has been on sc lanreotide injections now stretched to 30 mg every 5 weekly with 4-hourly oral feeds during the day and continuous overnight gastrostomy feeds. His blood glucose concentrations are currently stable, and he is able to fast for 8 h at the age of 3 years. The child has developed pancreatic exocrine insufficiency needing pancreatic enzyme supplements, and so far, he has not experienced any adverse reactions to lanreotide. His quality of life and fast tolerance improved after switching to monthly injections of the somatostatin analogue.
Case 3
A 21-day-old girl diagnosed with CHI on the first day of life was admitted to our hospital for further management of her condition. She was born at 39 +1 weeks' gestation with a birth weight of +0.03 SDS, and there was no history of gestational diabetes. She was unresponsive to maximum doses of diazoxide (20 mg/kg/day) and chlorothiazide (7.5 mg/kg/day). She was subsequently stabilised on iv infusion of glucagon (maximum: 5 μg/kg/h) and sc infusion of octreotide (maximum: 30 μg/kg/day), and this seemed to improve her blood glucose concentrations. At that point, genetic testing revealed a heterozygous nonsense ABCC8 gene mutation (p.G1401R), and subsequently the 18 F-DOPA-PET/CT scan confirmed a focal lesion in the head of the pancreas (Fig. 1) . The option of lesionectomy was discussed with the family, but due to the high risk of surgical complications, the parents preferred to attempt medical treatment.
Consequently, normoglycaemia was successfully established on sc octreotide injections (maximum: 35 μg/kg/day) 4 times per day and on 3-4-hourly oral feeds with a maximum fasting duration of 4 h. However, she still continued to have occasional hypoglycaemia, and at the age of 20 months, a trial with lanreotide (somatuline autogel) was commenced after parental consent. Fourweekly lanreotide at a dose of 30 mg achieved euglycaemia, and octreotide injections were weaned over 3 months and then stopped. Over the last 7 months, she has been on sc lanreotide injections 30 mg every 4 weeks, and on 4-5-hourly oral feeds. Her blood glucose is currently stable, she is able to fast for 12 h and has achieved appropriate neurodevelopmental milestones.
Discussion
Lanreotide is a synthetic octapeptide analogue of somatostatin, a naturally occurring inhibitory hormone that blocks the release of several other hormones, including growth hormone, thyroid-stimulating hormone, insulin, and glucagon. Lanreotide binds to the same receptors as somatostatin, although with higher affinity to peripheral receptors, and has similar activity. It has a high binding affinity for human somatostatin receptors (SSTR) 2 and SSTR5, and a reduced binding affinity for human SSTR1, SSTR3, and SSTR4. Given that lanreotide has a much longer half-life than somatostatin, it generates more prolonged effects [13] . The use of lanreotide in the treatment of acromegaly due to both pituitary and nonpituitary growth hormone-secreting tumours is welldocumented, as is its use in the management of symptoms caused by neuroendocrine tumours, particularly carcinoid tumours and VIPomas. Lanreotide also shows activity against non-endocrine tumours, and, along with other DOI: 10.1159/000491101 somatostatin analogues, is being studied as a possible general anti-tumour agent [14, 15] .
Recently, lanreotide has been used for the treatment of CHI. Three long-acting formulations, namely octreotide LAR, lanreotide acetate, and an aqueous slow-release depot preparation (autogel) have been developed in an effort to increase the dosing interval and provide a more sustained clinical effect [16] [17] [18] . Previous studies [19] [20] [21] [22] [23] concluded that lanreotide acetate may be a safe and effective alternative therapy in patients with diffuse forms of CHI, offering an improved quality of life, since it is well tolerated and contributes to a clear simplification of the medical care. It is recommended that longer follow-up of a larger patient cohort is needed to establish this therapeutic option for CHI patients and to define the optimal age for initiating treatment [19] . Shah et al. [22] reported a significantly improved outcome in quality of life after lanreotide injection in an adolescent with severe side effects due to diazoxide. Van der Steen et al. [23] have recently reported on two patients with focal CHI associated with paternal heterozygous mutations in the ABCC8 gene successfully treated, for a limited period of 2 and 6 months, with lanreotide until surgical excision of the focal lesion was performed. One patient did not experience any side effects, while the other patient developed mildly elevated liver enzymes (AST, ALT) and low IGF-1. In our case series, none of the patients demonstrated side effects within a period of 7-27 months, hence lanreotide remains their on-going therapy along with glucose-enriched feeds. Moreover, case 1 and case 3 have been on lanreotide therapy for 12 and 7 months, respectively, contributing to the avoidance of complex pancreatic surgery and its complications. We have also reported that, compared to other studies, a lower dose of lanreotide is sufficient to manage children with hyperinsulinism.
Lanreotide causes the same adverse effects as other somatostatin analogues [24] . A retrospective study of 27 patients with CHI who received long-acting somatostatin analogues reported side effects in 13 of the 27 patients (48%), without any life-threatening acute events, whilst in 3 patients (11%) medication was discontinued due to side effects [23] . Side effects included mild to moderate pain at the injection site and gastrointestinal disturbances, such as diarrhoea, nausea, vomiting, and, less frequently, necrotising enterocolitis. However, long-term treatment with lanreotide has been associated with gallstone formation, cholestatic jaundice, and elevated liver enzymes that are reversible after cessation of treatment [20, 23] . Furthermore, lanreotide can inhibit growth hormone and thyroid-stimulating hormone secretion causing growth issues or thyroid dysfunction. In conclusion, it is important to monitor for side effects in children on long-acting somatostatin analogue therapy.
These cases illustrate that focal CHI may be managed with lanreotide injections, even during the first years of life, especially in those CHI patients with inoperable focal lesions in the pancreatic head. This conservative therapeutic option seems to achieve adequate glycaemic control in CHI patients in a more acceptable manner (monthly injections instead of frequent daily octreotide injections) and is associated with fewer complications, such as gastrointestinal symptoms, hypertrichosis, reduced orality, obesity, and episodes of sepsis, than the previously used medical options (diazoxide, octreotide, and sirolimus). Furthermore, this therapeutic option was less stressful for the patients and their families, by either avoiding pancreatic surgery completely (cases 1 and 3), or by avoiding more extensive pancreatectomy (case 2). This is particularly important, as emerging evidence suggests that CHI might become milder with the passage of time [24] . Therefore, therapies such as lanreotide offer the patient the opportunity to avoid pancreatic surgery, and consequently its associated immediate and long-term post-operative complications. SSTR expression studies in focal and diffuse forms of CHI performed by our group show that SSTR2 is expressed in some focal pancreatic tissues (to be published). This suggests that lanreotide is likely to work in focal CHI due to its effect via SSTR2 to inhibit insulin secretion. However, more studies need to be undertaken to look for a correlation between genetics and SSTR expression in the islets. The beneficial therapeutic impact of lanreotide treatment observed in these patients should be confirmed in prospective studies, and the patients should be closely monitored for potential side effects.
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